Colgate-Palmolive COO Shane Grant Receives Annual Equity Grants (RSUs & Options)
COLGATE PALMOLIVE CO
Subscribe to track CL
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
š Form 4 Filing: COLGATE PALMOLIVE CO ($CL) Insider: Shane Grant (COO, Americas) Transaction Date: September 16, 2026
Details: ⢠Type: Award / Grant (RSUs) ⢠Shares Acquired: 7,355 Common Stock @ $0.00 ⢠Direct Post-Transaction Holdings: 79,503 shares ⢠Derivative Grant: 50,902 Stock Options (Exercise Price: $87.02, Expiration: 2036-09-16)
Significance: Low (Routine incentive compensation awards)
Comprehensive Analysis
Overview
On September 18, 2026, Colgate-Palmolive Co ($CL) filed a Form 4 disclosing equity award grants to Shane Grant, the company's Chief Operating Officer, Americas.
Transaction Details
- Non-Derivative Award: Shane Grant received a grant of 7,355 Restricted Stock Units (RSUs) under the issuer's incentive compensation plan on September 16, 2026. The award has an acquisition price of $0.00 and vests in equal one-third installments over three years.
- Derivative Award: Grant was also awarded 50,902 stock options with an exercise price of $87.02 per share, expiring on September 16, 2036. The options vest in one-third annual increments starting on the first anniversary of the grant date.
- Post-Transaction Beneficial Ownership: Following these awards, Grant directly holds 79,503 shares of Colgate-Palmolive common stock.
Market & Trading Significance
This transaction represents routine, plan-based executive compensation rather than open-market buying or selling activity. Consequently, it carries Low predictive signal for stock performance.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.
